Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy

被引：61

作者：

Kopylov, Uri ^{[1
,2
,3
]}

Hanzel, Jurij ^{[4
]}

Liefferinckx, Claire ^{[5
]}

De Marco, Davide ^{[3
]}

Imperatore, Nicola ^{[6
]}

Plevris, Nikolas ^{[7
]}

Baston-Rey, Iria ^{[8
]}

Harris, Richard J. ^{[9
]}

Truyens, Marie ^{[10
]}

Domislovic, Viktor ^{[11
]}

Vavricka, Stephan ^{[12
]}

Biemans, Vince ^{[13
,14
]}

Myers, Sally ^{[15
]}

Sebastian, Shaji ^{[15
]}

Ben-Horin, Shomron ^{[1
,2
]}

Gonzalez Lama, Yago ^{[16
]}

Gilletta, Cyrielle ^{[17
]}

Ariella, Bar-Gil Shitrit ^{[18
]}

Zelinkova, Zuzana ^{[19
]}

Weishof, Roni ^{[20
,21
]}

Storan, Darragh ^{[22
,23
]}

Zittan, Eran ^{[24
]}

Farkas, Klaudia ^{[25
]}

Molnar, Tamas ^{[25
]}

Franchimont, Denis ^{[5
]}

Cremer, Anneline ^{[5
]}

Afif, Waqqas ^{[3
]}

Castiglione, Fabiana ^{[6
]}

Lees, Charles ^{[7
]}

Barreiro-de Acosta, Manuel ^{[8
]}

Lobaton, Triana ^{[10
]}

Doherty, Glen ^{[22
,23
]}

Krznaric, Zeljko ^{[20
,21
]}

Pierik, Marieke ^{[13
]}

Hoentjen, Frank ^{[14
]}

Drobne, David ^{[4
,26
]}

机构：

[1] Sheba Med Ctr, Dept Gastroenterol, Ramat Gan, Israel

[2] Tel Aviv Univ, Sackler Med Sch, Tel Aviv, Israel

[3] McGill Univ, Div Gastroenterol, Hlth Ctr, Montreal, PQ, Canada

[4] Univ Med Ctr Ljubljana, Dept Gastroenterol, Ljubljana, Slovenia

[5] ULB, Dept Gastroenterol, Hop Erasme, Brussels, Belgium

[6] Sch Med Federico II Naples, Dept Clin Med & Surg, Gastroenterol, Naples, Italy

[7] Western Gen Hosp, Edinburgh IBD Unit, Edinburgh, Midlothian, Scotland

[8] Hosp Clin Univ Santiago de Compostela, Serv Aparato Digest, Unidad EII, Santiago De Compostela, A Coruna, Spain

[9] Univ Hosp Southampton NHS Fdn Trust, Dept Gastroenterol, Southampton, Hants, England

[10] Ghent Univ Hosp, Dept Gastroenterol, Ghent, Belgium

[11] Univ Hosp Ctr Zagreb, Dept Gastroenterol & Hepatol, Zagreb, Croatia

[12] Ctr Gastroenterol & Hepatol, Zurich, Switzerland

[13] Maastricht Univ, Med Ctr, Dept Internal Med, Div Gastroenterol & Hepatol, Maastricht, Netherlands

[14] Radboud Univ Nijmegen, Med Ctr, Dept Gastroenterol & Hepatol, Nijmegen, Netherlands

[15] Hull Univ Teaching Hosp NHS Trust, IBD Unit, Kingston Upon Hull, N Humberside, England

[16] Hosp Univ Puerta de Hierro, Gastroenterol & Hepatol Dept, IBD Unit, Madrid, Spain

[17] CHU Toulouse Rangueil, Serv Gastroenterol & Nutr, Toulouse, France

[18] Hebrew Univ Jerusalem, Shaare Zedek Med Ctr, Med Sch, IBD MOM Unit,Digest Dis Inst, Jerusalem, Israel

[19] St Michaels Hosp, Dept Gastroenterol & Gastrointestinal Endoscopy, Bratislava, Slovakia

[20] Rambam Hlth Care Campus, Gastroenterol Dept, Haifa, Israel

[21] Technion Israel Inst Technol, Bruce Rappaport Sch Med, Haifa, Israel

[22] Univ Coll Dublin, St Vincents Univ Hosp, Ctr Colorectal Dis, Dublin, Ireland

[23] Univ Coll Dublin, Sch Med, Dublin, Ireland

[24] Emek Med Ctr Afula Israel, Ellen & Pinchas Mamber Inst Gastroenterol & Liver, IBD Unit, Afula, Israel

[25] Univ Szeged, Dept Med 1, Fac Med, Szeged, Hungary

[26] Univ Ljubljana, Med Fac, Ljubljana, Slovenia

来源：

ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2020年 / 52卷 / 01期

关键词：

INDUCTION; EXPERIENCE;

D O I：

10.1111/apt.15784

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background Ustekinumab is effective in Crohn's disease. However, a substantial proportion of patients will not respond or lose response to ustekinumab. The current evidence to support the effectiveness of dose-optimisation for ustekinumab nonresponse is limited. Aim To assess the effectiveness of dose escalation of ustekinumab. Methods This was a multicentre retrospective cohort study. We included active Crohn's disease patients who received a standard-dose intravenous induction and at least one subcutaneous ustekinumab 90 mg dose. All enrolled patients received dose escalation by either shortening the interval between the doses to every 4 or 6 weeks, intravenous reinduction or a combination of strategies. The primary outcome of the study was clinical response at week 16 after dose escalation. Results A total of 142 patients (22 centres/14 countries) were included. The patients were dose-escalated after a median treatment duration of 30 weeks. At week 16 from escalation, 73/142 (51.4%) responded to treatment, including 55/142 (38.7%) in clinical remission. Corticosteroid-free remission was achieved in 6/34 (17.6%) patients on corticosteroids at the time of escalation; 118/142 (83%) continued treatment beyond week 16. Follow-up data beyond week 16 were available for 74/118 (62.7%) patients. On the last follow-up, 51/98 (52%) patients with available data responded to treatment, including 41/98 (42%) in clinical remission. Conclusions Intensification of ustekinumab maintenance dosage was effective in over 50% of the patients. This strategy should be considered in patients who are nonresponsive to every 8 weeks ustekinumab maintenance dosing.

引用

页码：135 / 142

页数：8

共 50 条

[21] Efficacy, Safety and Timing of Dose Adjustment of Subcutaneous Ustekinumab Maintenance in Moderate -Severe Crohn's Disease Patients in IM-UNITI
Bruce, Sands
Christopher, Gasink
Douglas, Jacobstein
Gao Long-Long
Jewel, Johanns
Philippe, Szapary
Jean-Frederic, Colombel
Stephan, Targan
Subrata, Ghosh
William, Sandborn
[J]. INFLAMMATORY BOWEL DISEASES, 2017, 23 : S9 - S9
[22] Real-World Effectiveness of Ustekinumab Dose Intensification in Crohn's Disease
Srinivasan, Ashish
van Langenberg, Daniel
De Cruz, Peter
[J]. INFLAMMATORY BOWEL DISEASES, 2021, 27 (06) : E69 - E69
[23] Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia
Kantarjian, HM
Talpaz, M
O'Brien, S
Giles, F
Garcia-Manero, G
Faderl, S
Thomas, D
Shan, JQ
Rios, MB
Cortes, J
[J]. BLOOD, 2003, 101 (02) : 473 - 475
[24] Dose escalation of imatinib may improve responses in patients with CML who fail standard-dose imatinib - Response
Cortes, J
[J]. BLOOD, 2003, 102 (07) : 2703 - 2704
[25] Incidence and Predictors of Clinical Response, Re-induction Dose, and Maintenance Dose Escalation with Certolizumab Pegol in Crohn's Disease
Stein, Adam C.
Rubin, David T.
Hanauer, Stephen B.
Cohen, Russell D.
[J]. INFLAMMATORY BOWEL DISEASES, 2014, 20 (10) : 1722 - 1728
[26] Time of infliximab therapy initiation and dose escalation in Crohn's disease
Mindy CW Lam
Terry Lee
Kenneth Atkinson
Brian Bressler
[J]. World Journal of Gastroenterology, 2014, (01) : 214 - 218
[27] Time of infliximab therapy initiation and dose escalation in Crohn's disease
Lam, Mindy C. W.
Lee, Terry
Atkinson, Kenneth
Bressler, Brian
[J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (01) : 214 - 218
[28] USTEKINUMAB DOSE INTENSIFICATION IN PAEDIATRIC CROHN'S DISEASE
Rodriguez-Mauriz, Rosa
Segui Solanes, Carlos
Masiques Mas, Isabel
Rudi Sola, Nuria
[J]. JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2021, 57 (07) : 1149 - 1149
[29] EFFICACY OF DOSE INTENSIFICATION OF USTEKINUMAB IN CROHN'S DISEASE
Ramaswamy, Pradeep Kakkadasam
Moattar, Hadi
Sawyer, Elise A.
James, Rayshelle
Edwards, John
Shukla, Dheeraj
[J]. GASTROENTEROLOGY, 2020, 158 (06) : S956 - S956
[30] Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
Feagan, B. G.
Sandborn, W. J.
Gasink, C.
Jacobstein, D.
Lang, Y.
Friedman, J. R.
Blank, M. A.
Johanns, J.
Gao, L. -L.
Miao, Y.
Adedokun, O. J.
Sands, B. E.
Hanauer, S. B.
Vermeire, S.
Targan, S.
Ghosh, S.
de Villiers, W. J.
Colombel, J. -F.
Tulassay, Z.
Seidler, U.
Salzberg, B. A.
Desreumaux, P.
Lee, S. D.
Loftus, E. V., Jr.
Dieleman, L. A.
Katz, S.
Rutgeerts, P.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (20): : 1946 - 1960

← 1 2 3 4 5 →